920 related articles for article (PubMed ID: 18171251)
1. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole plasma monitoring.
Pasqualotto AC; Shah M; Wynn R; Denning DW
Arch Dis Child; 2008 Jul; 93(7):578-81. PubMed ID: 18252755
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
13. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
14. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
15. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
16. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A; Nieth V; Calandra T; Bille J; Bolay S; Decosterd LA; Buclin T; Majcherczyk PA; Sanglard D; Marchetti O
Antimicrob Agents Chemother; 2007 Jan; 51(1):137-43. PubMed ID: 17088483
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
18. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
